Best GLP-1 for Weight Loss
It is the most asked question in this whole category, and the honest answer is that no single GLP-1 is best for everyone. The two pens approved for weight management, Wegovy and Zepbound, differ in ingredient, schedule shape and price, and the trial results behind them come with a caveat that matters. This page compares them fairly and gives you the decision framework prescribers actually use, instead of crowning a winner that would be wrong for half the people reading it.
The weight management options at a glance
| Detail | Wegovy | Zepbound |
|---|---|---|
| Active ingredient | Semaglutide, a GLP-1 receptor agonist | Tirzepatide, which acts on both GIP and GLP-1 receptors |
| Approved for | Weight management | Weight management, and obstructive sleep apnea in adults with obesity |
| How often | One injection, once a week | One injection, once a week |
| Max weekly dose | 2.4 mg, the label maintenance dose | 15 mg maximum; label maintenance doses are 5 mg, 10 mg or 15 mg |
| Trial result | In STEP 1, people lost an average of 14.9 percent of body weight over 68 weeks | In SURMOUNT-1, people on the 15 mg dose lost an average of 20.9 percent of body weight over 72 weeks |
| About list price per month | About $1,350 | About $1,060 |
Read the trial row with care. STEP 1 and SURMOUNT-1 were separate trials, run in different groups of people over different lengths of time. They were not a head to head comparison, so the two percentages cannot be used to say that one medicine beats the other for any individual person.
Why there is no single best
Every trial result is an average across hundreds of people whose individual results spread widely on both sides of it. Some people lose far more than the average on either medicine; some lose little on either. On top of that, a medicine only delivers anything if you can stay on it, and staying on it depends on side effects, which are personal, and on coverage, which is practical. A page that crowns one pen for everyone is ignoring all three of those facts. What can be compared fairly is the evidence, the schedules, the labels and the prices, and that is what this page does.
What the trial programs show, with the caveat attached
The two flagship weight trials reported averages of 14.9 percent body weight lost over 68 weeks in STEP 1, at the 2.4 mg semaglutide dose, and 20.9 percent over 72 weeks in SURMOUNT-1, at the 15 mg tirzepatide dose. Those trials were separate studies, with different groups of people and different durations, and they were not a head to head comparison. Treat the gap between the numbers as a signal worth discussing with a prescriber, not as a promise about your own result on either pen. You can see what the averages would mean at your own starting weight in the GLP-1 weight loss calculator.
The factors that actually decide it
- Your diagnosis and the label. Weight management labels are Wegovy and Zepbound. If type 2 diabetes is part of your picture, the diabetes labels, Ozempic and Mounjaro, enter the conversation, and Zepbound also carries a sleep apnea approval in adults with obesity.
- Tolerability. Both families share gastrointestinal side effects, worst while doses climb. Which one you can stay on at a useful dose matters more than a trial average.
- The shape of the schedule. Wegovy climbs to one fixed maintenance dose. Zepbound offers three maintenance doses, so the settling point is flexible. The full schedules are on the Wegovy dosage chart and Zepbound dosage chart pages.
- Price and coverage. List prices are about $1,350 a month for Wegovy and about $1,060 for Zepbound, before insurance. The pen your plan covers is often the realistic starting point. The cheapest GLP-1 without insurance guide ranks the wider field.
- Your prescriber's judgment. They know your history, your other medicines and your earlier responses, and they carry responsibility for the choice.
Questions to take to your prescriber
- Which label fits my situation, weight management, diabetes, or both?
- Given my history, which ingredient would you start with, and why?
- What will we do if side effects limit the dose?
- What result at three and six months would count as this working?
- Which of these will my insurance actually cover?
Switching is part of the picture
Not settling on the first pen is normal care, not failure. People switch because of plateaus, tolerability or coverage, and the comparisons on this site, including Wegovy vs Zepbound and semaglutide vs tirzepatide, lay out what changes when you do. Switching is always a prescriber decision, never a self switch, and the new medicine restarts from its own published schedule.
Frequently asked questions
What is the best GLP-1 for weight loss?
There is no single best. The two weight management labels are Wegovy, with a list price of about $1,350 a month, and Zepbound, at about $1,060. The suitable choice depends on your diagnosis, how you tolerate the dose climbs, your other conditions, such as sleep apnea, which is on Zepbound's label, and what your insurance covers. That is why this page compares factors rather than naming one winner.
Which GLP-1 has the biggest trial weight loss?
The largest published average is from SURMOUNT-1, where tirzepatide at 15 mg averaged 20.9 percent weight loss over 72 weeks, against 14.9 percent over 68 weeks in STEP 1 for semaglutide at 2.4 mg. Those were separate trials with different people and durations, not a head to head study, so the numbers describe trial programs, not a guaranteed ranking for any individual.
Is the cheapest GLP-1 the best place to start?
Price is one factor, not the deciding one. The branded weight management pens list at about $1,060 to $1,350 a month, and coverage changes the real figure completely. Cheaper compounded products are a different category: they are not FDA approved versions of these medicines and carry their own cautions, which the compounded semaglutide guide on this site sets out.
Does the best GLP-1 differ if I have diabetes?
It can. With type 2 diabetes in the picture, the diabetes labels, Ozempic for semaglutide and Mounjaro for tirzepatide, are usually where prescribing starts, because blood sugar control becomes a treatment goal alongside weight. Your prescriber will weigh both goals together rather than treating weight in isolation.
Can I change if the first GLP-1 does not suit me?
Yes. Switching between these medicines is a normal part of care when side effects, a plateau or coverage get in the way. It is always a prescriber decision, never a self switch: the new medicine starts from its own published schedule, and the two are not overlapped.